![A scientist pointing to an image of a DNA chain.](/sites/default/files/2019-04/GettyImages-645455760_0.jpg)
Clinical Trial Search Results
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis
This study is being done to help answer the following research questions: (a) How mirikizumab, an investigational drug, could help people with ulcerative colitis over time; (b) How safe long-term use of mirikizumab is; and (c) ...
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease.
The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions: How safe mirikizumab is and whether you might have any side effects when you t ...
A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.
This study will look at the efficacy and safety of combined treatment with 2 anticancer drugs, which are called tislelizumab (also known as BGB-A317) and BGB-A1217 compared to treatment with pembrolizumab and saline (a mix of s ...
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Examine the Efficacy and Safety of ZX008 in Subjects with CDKL5 deficiency disorder followed by an Open-Label Extension.
The purpose of this informed consent form is to collect data about the non-paid caregiver of a subject that is participating in ZX008-2103 study. You, as the non-paid caregiver, are being asked to complete the EQ-5D-5L Quality ...
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDl3280A (Anti−PD-L1 Antibody) In Combination with Carboplatin and Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer
[Abbreviated - Closed] The purpose of this study is to look at the effects, good or bad, of MPDL3280A on you and the specific type of lung cancer (non−small cell lung cancer [NSCLC]) from which you are suffering. MPDL3280A is a ...
A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-Derived Stem Cells (eASC), for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease Over a Period of 24 Weeks and a Follow-Up Period Up to 52 Weeks. ADMIRE-CD II Study.
The purpose of this study is to confirm (1) how well the study drug works at a single dose of 120 million cells compared to a placebo; (2) how safe and tolerable the study drug is in patients with fistulizing CD.
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
The purpose of this optional study is to test for biomarkers that help to understand the relationship between the study drug and your tumor.
A Prospective, Multi-Center Investigation of the da Vinci SP Surgical System in Colorectal Procedures for Benign and Malignant Disease.
The purpose of this study is to collect data to evaluate safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in colorectal procedures. These colorectal procedures consist of low anterior resec ...
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Subjects in Part 1 (Dose Finding Phase) Only: The overall goals of this study are: (1) to compare the effects, good and/or bad, of a new combination of chemotherapy using VAC/VI plus temsirolimus; (2) to find if adding the drug ...